We are a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Our lead compound, emricasan, is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases, which are enzymes that mediate inflammation and apoptosis. We believe that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease and potentially provide treatment options in multiple areas of liver disease. We have observed compelling preclinical and clinical trial results that suggest emricasan may have clinical utility in slowing progression of liver disease regardless of the original cause of the disease. To date, emricasan has been studied in over 650 subjects in sixteen clinical trials across a broad range of liver disease etiologies and stages of progression. In multiple clinical trials, emricasan has demonstrated statistically significant, consistent, rapid and sustained reduction in elevated levels of key biomarkers of inflammation and apoptosis implicated in the severity and progression of liver disease. Importantly, these key biomarkers are known to be elevated and to have prognostic value in multiple hepatic indications that we are currently pursuing. In December 2016, Conatus announced an exclusive option, collaboration and license agreement with Novartis for the global development and commercialization of emricasan.
View Top Employees from Conatus Pharmaceuticals Inc.Website | http://www.conatuspharma.com/ |
Ticker | CNAT |
Revenue | $33 million |
Funding | $121 million |
Employees | 26 (11 on RocketReach) |
Founded | 2005 |
Address | 16745 W Bernardo Dr. Ste. 250, San Diego, California 92127, US |
Phone | (858) 376-2600 |
Technologies |
JavaScript,
HTML,
Font Awesome
+20 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Drug Manufacturing & Research, Science and Engineering, Healthcare, Health Care, Therapeutics |
Web Rank | 3 Million |
Keywords | Conatus Pharmaceuticals, Conatus Therapeutics, Conatus Pharmaseuticals News, Conatus Investor Relations, Late Breaker Presentation At Liver Congress |
Competitors | ASLAN Pharmaceuticals, Alios BioPharma, Cocrystal Pharma, Inc., CymaBay Therapeutics, MyoKardia |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 5419 Companies, NAICS Code 541 Companies |
Looking for a particular Conatus Pharmaceuticals Inc. employee's phone or email?
The Conatus Pharmaceuticals Inc. annual revenue was $33 million in 2023.
Charles Cashion is the Senior Vice President and Chief Financial Officer of Conatus Pharmaceuticals Inc..
11 people are employed at Conatus Pharmaceuticals Inc..
Conatus Pharmaceuticals Inc. is based in San Diego, California.
The NAICS codes for Conatus Pharmaceuticals Inc. are [54, 325, 3254, 32541, 32, 5419, 541].
The SIC codes for Conatus Pharmaceuticals Inc. are [28, 283].